CholedocholithiasisNCT07283185
Prospective Comparison of the Carbon Footprint of EUS vs MRCP for Evaluation of Suspected Choledocholithiasis
An observational study of Choledocholithiasis, run by Asian Institute of Gastroenterology, India at 1 site in India.
Trial summary
MRCP and EUS are diagnostically equivalent in detecting CBD stones among patients with intermediate risk, as shown in a landmark RCT. However, MRI-based imaging is power-intensive, requiring large infrastructure and long scan durations. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Choledocholithiasis
- How many people
- 200 participants
- Where
- 1 siteIndia
- Study dates
- 1 Dec 2025to Nov 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients (>18 years - 80years) with suspected choledocholithiasis and classified as intermediate risk per ESGE guidelines, undergoing either EUS or MRCP.
Who may be able to join
- Age ≥18 years
- Intermediate likelihood of CBD stone (per ESGE)
- Undergoing either MRCP or EUS for evaluation
Who cannot join
- High or low likelihood category (per ESGE)
- Undergoing both MRCP and EUS simultaneously
- Contraindications to either modality
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
India1 site, 1 recruiting
- Recruiting
AIG Hospitals
Hyderabad, Telangana, 500032
Deepa Shukla, PhD, 9953900117, deepa.shukla@aighospitals.com
Hardik Rughwani, MD, DM
About this study
Official title: Prospective Comparison of the Carbon Footprint of Endoscopic Ultrasound (EUS) vs Magnetic Resonance Cholangiopancreatography (MRCP) for Evaluation of Suspected Choledocholithiasis
MRCP and EUS are diagnostically equivalent in detecting CBD stones among patients with intermediate risk, as shown in a landmark RCT. However, MRI-based imaging is power-intensive, requiring large infrastructure and long scan durations. EUS, a less energy-consuming and portable procedure, has the added advantage of enabling same-session ERCP, reducing the need for repeat procedures.
Read the detailed description
MRCP and EUS are diagnostically equivalent in detecting CBD stones among patients with intermediate risk, as shown in a landmark RCT. However, MRI-based imaging is power-intensive, requiring large infrastructure and long scan durations. EUS, a less energy-consuming and portable procedure, has the added advantage of enabling same-session ERCP, reducing the need for repeat procedures. Prior research confirms that diagnostic EUS generates significantly less CO₂e per procedure compared to radiologic imaging. This study aims to support sustainable diagnostic choices by quantifying their environmental footprint.
- Conditions
- Choledocholithiasis
- Medical subject headings
- Choledocholithiasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| EUS | Patients scheduled for Endoscopic Ultrasound | |
| MRCP | Patients scheduled for Magnetic Resonance Cholangiopancreatography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total kg CO₂e per procedure for EUS vs MRCP.
Total kg CO₂e per procedure for EUS vs MRCP.
Measured: 12 months
Secondary outcomes (1)
Emissions
Emissions per accurate diagnosis Emissions broken down by source (electricity, consumables, travel) Recommendations for sustainable diagnostic practices
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Dec 2025
- Study start1 Dec 2025
- Primary completionNov 2026 (estimated)
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for CholedocholithiasisStudies of the same condition, open and under way.
- More trials run by Asian Institute of Gastroenterology, IndiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Asian Institute of Gastroenterology, India
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07283185
- Sponsor's protocol ID
- EUS vs MRCP-CBD1
- Status last verified
- Oct 2025
- First submitted
- 2 Dec 2025
- Last updated
- 6 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
• McAlister S et al. Radiology. 2021. Imaging footprint
• Lenzen M et al. Lancet Planet Health. 2020. Health care emissions
• Rughwani H et al. Gut. 2025. Carbon footprint of GIE
• Jagtap N et al. Gut. 2022. EUS versus MRCP RCT
Rughwani H, Jagtap N, de Jong DM, Tyagi A, Putta T, Pasumarthy A, Khair Khan A, Kalapala R, Ramchandani M, Lakhtakia S, Reddy DN. Greener Choices in Biliary Imaging: A Prospective Carbon Footprint Comparison of Endoscopic Ultrasound Versus Magnetic Resonance Cholangiopancreatography for Intermediate-Likelihood Choledocholithiasis. Clin Transl Gastroenterol. 2026 Sep 8. doi: 10.14309/ctg.0000000000001098. Online ahead of print.
PubMed 42709924
Study at a glance
From the registry record, last updated by the sponsor on 6 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Comparison of the Carbon Footprint of Endoscopic Ultrasound (EUS) vs Magnetic Resonance Cholangiopancreatography (MRCP) for Evaluation of Suspected Choledocholithiasis
- ClinicalTrials.gov ID
- NCT07283185
- Acronym / sponsor ID
- EUS vs MRCP-CBD1
- Conditions
- Choledocholithiasis
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Asian Institute of Gastroenterology, IndiaUniversity, hospital or other
- Study start
- 1 Dec 2025 (actual)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- Nov 2026 (estimated)
- First posted
- 15 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
MRCP and EUS are diagnostically equivalent in detecting CBD stones among patients with intermediate risk, as shown in a landmark RCT. However, MRI-based imaging is power-intensive, requiring large infrastructure and long scan durations. EUS, a less energy-consuming and portable procedure, has the added advantage of enabling same-session ERCP, reducing the need for repeat procedures.
Detailed description
MRCP and EUS are diagnostically equivalent in detecting CBD stones among patients with intermediate risk, as shown in a landmark RCT. However, MRI-based imaging is power-intensive, requiring large infrastructure and long scan durations. EUS, a less energy-consuming and portable procedure, has the added advantage of enabling same-session ERCP, reducing the need for repeat procedures. Prior research confirms that diagnostic EUS generates significantly less CO₂e per procedure compared to radiologic imaging. This study aims to support sustainable diagnostic choices by quantifying their environmental footprint.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| EUS | – | –Patients scheduled for Endoscopic Ultrasound |
| MRCP | – | –Patients scheduled for Magnetic Resonance Cholangiopancreatography |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients (>18 years - 80years) with suspected choledocholithiasis and classified as intermediate risk per ESGE guidelines, undergoing either EUS or MRCP.
Key inclusion criteria (3 listed)
- Age ≥18 years
- Intermediate likelihood of CBD stone (per ESGE)
- Undergoing either MRCP or EUS for evaluation
Key exclusion criteria (3 listed)
- High or low likelihood category (per ESGE)
- Undergoing both MRCP and EUS simultaneously
- Contraindications to either modality
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Total kg CO₂e per procedure for EUS vs MRCP.
Time frame: 12 months
Total kg CO₂e per procedure for EUS vs MRCP.
1 secondary outcome
Emissions
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jan 2026.
- Results publication• McAlister S et al. Radiology. 2021. Imaging footprint
- Results publication• Lenzen M et al. Lancet Planet Health. 2020. Health care emissions
- Results publication• Rughwani H et al. Gut. 2025. Carbon footprint of GIE
- Results publication• Jagtap N et al. Gut. 2022. EUS versus MRCP RCT
- Derived from this study: PubMed 42709924Rughwani H, Jagtap N, de Jong DM, Tyagi A, Putta T, Pasumarthy A, Khair Khan A, Kalapala R, Ramchandani M, Lakhtakia S, Reddy DN. Greener Choices in Biliary Imaging: A Prospective Carbon Footprint Comparison of Endoscopic Ultrasound Versus Magnetic Resonance Cholangiopancreatography for Intermediate-Likelihood Choledocholithiasis. Clin Transl Gastroenterol. 2026 Sep 8. doi: 10.14309/ctg.0000000000001098. Online ahead of print.
Related trials for Choledocholithiasis
Not yet recruiting
Supraglottic Oxygenation Via Oral Transtracheal Catheter for Reducing the Incidence of Hypoxemia During ERCP Under Sedation
Choledocholithiasis With Cholecystitis With Obstruction, Obstructive Jaundice
Recruiting
ChOlecystectomy aFter successFul Endoscopic Common Bile Duct Stone Extraction in Elderly
Cholecystectomy, Laparoscopic, Choledocholithiasis
Recruiting
Hyoscine Butylbromide During Transcystic Papillary Balloon Dilation for Choledocholithiasis
Choledocholithiasis, Common Bile Duct Stones
Not yet recruiting
EUS-Guided Gallbladder Drainage Versus Conservative Management in Patients Unfit for Surgery After a Biliary Event Without Cholecystitis. DRECON Study
Cholecystectomy, Gallbladder
RecruitingObservational study
Treatment Outcomes and Complications of Three Therapeutic Approaches for Concomitant Choledocholithiasis and Cholecystolithiasis
Cholelithiasis Associated With Common Bile Duct Stones
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Choledocholithiasis, run by Asian Institute of Gastroenterology, India at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dr.Hardik Rughwani (9426928600, dr.hardikr@aighospitals.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total kg CO₂e per procedure for EUS vs MRCP. (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07283185, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jan 2026.